Our proprietary portfolio in #rarediseases continues to progress and Eleva is exploring a global strategy to evaluate these programs in patients starting 2025 🇩🇪 🇮🇳. C3 glomerulopathy, or #C3G for short, is one of the complement disorders Eleva is targeting. Since the prevalence of C3G in India is considered much higher compared to other regions, local KOLs have gathered considerable expertise in treating patients affected by the condition. 🛫 We are proud to have made first connections in India in an early effort to understand the clinical network serving these patients. Our growing clinical development team led by Karin Heidenreich and Dr. Martin Bauer, MD has recently spent an extended period in the region to introduce Eleva's potential solution to KOLs and medical practitioners. 🗓 We are equally proud that one of the top KOLs from India, Prof. Dr. Dinesh Khullar, joined our team and fellow KOL and complement expert Prof. Dr. Peter Zipfel for our clinical development webcast. Our guest speakers shared their knowledge and expertise on #factorH, #C3G, the #clinicalpractice in India, and #complementdisorders at large. To watch the replay, please go to: https://lnkd.in/eRJmEFDm Prof. Khullar reminded us that even a rare disease such as C3G statistically affects more than 1 million patients in a country of India’s size. We also learned that access to approved treatment options in C3G, often taken for granted in the western world, is not such an easy task in India. We thank both speakers and all participants for joining us in this first webcast session! www.elevabiologics.com Oviya MedSafe, Dr Vijay Venkatraman Janarthanan, KarthikaPandi Jeyachandran, Deepti Goel, Fabienne Zeitter
Deepti Goel
6mo
Proud to be a part of this mission. C3G, a rare disease is not so rare in India and the access to approved treatment options is not easy in India. Great start and wishing continued success 👍
Björn Cochlovius
6mo
Proud to be part of this exciting endeavour, developing solutions for underserved patients!
As an organization, Oviya MedSafe is proud to partner with eleva on this significant mission of yours in India! We deeply appreciate eleva for your intention to bring their novel therapeutic product for C3 glomerulopathy to India. We are delighted to be working with an organization like eleva that shares our vision and values. We wish you all success in this journey which we are honoured to be a part of! #c3glomerulopathy #c3g #India #Germany #webinar #recording #kidneydiseases #nephrology #research #clinicaldevelopment